九州体育BET9官网

BCHT, always attaching great importance to R&D and optimize the allocation of resources continuously, is fully equipped for biological vaccine research and pilot production with laboratories and pilot plants covering totally nearly 9,700 ㎡ and more than 1,180 sets of various advanced experimental equipments or instruments, and can meet the demands of simultaneous R&D on the virus culture scale-up technology platform, final product and adjuvant technology platform, genetic engineering technology platform, and bacterial vaccine technology platform.